This article is a small piece of mind intended to scrutinize the international asthma guidelines with a sprinkle of subtle criticism toward standard guidelines. As aspiring doctors, we must not always merely adopt international standards, but always stay armed with our knowledge and regional experience to improve, innovate, and revolutionize them to reach utmost efficiency and productivity. The aim of this work is to review old national and international clinical judgment and the recent guidelines of asthma management in an attempt to look at an alternate view on asthma medications. The article concludes that, in the context of escalation and de-escalation therapies for asthma, one should consider independent future risk factors in asthma control, based on clustering of asthma phenotypes and rather than upon patients' symptoms.
Background
In the last meeting of the Egyptian Society of Chest Diseases and Tuberculosis held to upgrade Egyptian guidelines for asthma management and prevention, there were many issues that had to be addressed. First, how to assess asthma control with respect to symptoms and future risks? Second, is asthma severity assessed as mild/moderate/severe according to controlling medications given or according to asthma phenotypes? The third and final question is what possible interventional therapy is best adopted for minimizing exacerbations? To answer these questions, we reviewed Global Initiative for Asthma (GINA) guidelines for asthma management and prevention.
Introduction
Like all management strategies, the Egyptian guidelines for asthma management in 2006 was primarily focused on the stepwise approach that is simple to understand and easy to use by pulmonologists and other specialists, including primary care and general practice physicians. For many years, there were many challenging aspects faced during the implementation of the Egyptian guidelines, diagnosis of asthma [1, 2] , and the nonavailability of spirometry in most health care facilities. Observed data also demonstrated that the pattern of asthma control was not related to novel types of inhalational device, but rather to educational aspect of how to use inhalers [3] .
High indoor pollution [4] , patients' adherence, and inappropriate drug prescription were found to be important contributing factors in the profile of nonasthma control in our country [5] . The roles of inhaled corticosteroids and long-acting bronchodilator in asthma management, in general, depend on (among others) patient symptoms.
Peer-reviewed guidelines: the window of opportunity
The National Asthma Education and Prevention Program in its expert panel report [3] declared that there was inadequate data to correlate the frequency of exacerbations with the level of asthma severity. Patients who had two or more exacerbations requiring oral systemic steroids in the past 6 months or wheezing episodes in the past year and who have risk factors for persistent asthma may be considered similar to patients who have persistent asthma, even in the absence of impairment level consistent with persistent asthma, from the treatment point of view [6] .
GINA 2014, representing the major revision of the global strategy report of asthma since 2006, provided a novel asthma definition in the forum of understanding airway diseases. It recognizes the heterogeneity of asthma and its phenotypes [7] . The key messages were that a therapeutic decision should be based not only on assessment of symptoms, but also on risk factors for exacerbations and/or development of fixed-airflow limitation [8] . This was followed exclusively in GINA 2015 with novel norms: the diagnosis of asthma-COPD syndrome. Albeit, a specific definition of Asthma-COPD syndrome was not provided at that time [9] . It did not encourage use of high-dose inhaled corticosteroids (ICS) in preschool children for asthma exacerbation or wheezing episodes in this age group.
Straight after, the GINA report was updated in 2016, postulating the low-dose ICS treatment for any asthma symptom plus any risk factor(s) for exacerbations [requiring oral corticosteroids (OCS)] within the last 12 months, ever in intensive care for asthma or low forced expiratory volume in 1 s (FEV 1 ). It advocated a low-dose ICS/formoterol as maintenance and reliever regimen for patients who had one or more exacerbations in the last year. In addition to this, new changes in step 4 treatments: add-on tiotropium as an extension to patients aged more than or equal to 12 years with a history of exacerbations. There was also an add-on therapy in step 5 treatments for patients with severe asthma: mepolizumab (anti-interleukin 5) for patients aged more than or equal to 12 years with severe eosinophilic asthma [10] .
Then, GINA 2017 emphasized the concept of asthma management being a practical approach in clinical practice rather than a mere guideline. It considered sublingual immunotherapy to adults sensitive to house dust mites with allergic rhinitis and exacerbations, despite ICS treatment, providing that FEV 1 is 70% predicted [11] . In addition, elevated exhaled nitric oxide in allergic patients was added to the list of independent predictors of exacerbations. It also addressed lung function, periodically recorded at least every 1-2 years or more often in higher risk patients. NICE guidelines 2017 emphasized risk stratification in asthma management. This risk stratification included many factors such as nonadherence to asthma medicine, psychological problems, unscheduled care for asthma, and severe exacerbation or hospitalization [12] .
Currently, GINA 2018 addressed new risk factors, even if the patient has few symptoms. They include higher bronchodilator reversibility with low FEV 1 , having one exacerbation or more in the last 12 months or ever intubated for asthma. Addition of LABA to ICS improves symptoms and lung function compared with the same dose of ICS alone, but with only a small reduction in reliever use [13] . It also emphasized SABA as per needed and not on a regular base in the follow up visit(s).
GINA 2018 [14] also specified persistent airflow limitation in patients with several different forms of airway diseases or phenotypes caused by a range of different underlying mechanisms. For example, exhaled nitric oxide-guided treatment was associated with significantly fewer exacerbations or a lower exacerbation rate rather than 'treatment-based' guidelines.
Sputum-guided treatment for patients with persistent symptoms and/or exacerbations may be justified based on eosinophilia more than 3% in induced sputum [15] , despite high-dose ICS or ICS/Long-Acting Beta(2) Agonist (LABA) treatment. In severe asthma, this strategy leads to reduced exacerbation and/or lower dose of ICS. On the contrary, vaccination has not proven to reduce the frequency or severity of asthma exacerbation [16] .
Exacerbation, often representing a failure in chronic asthma care, provides opportunities to review the patient's asthma management. One of the suggested regimens for patients with more than one severe exacerbation in the last 12 months is stepping up the treatment, provided there is a lack of modifiable risk factors [14] .
What is the window of opportunity?
Most literatures confer the role of inhaled steroids in asthma therapy aiming to control the symptoms, and a few went on to describe doubling or even quadrupling the dose in acute exacerbation, but those were primarily focused on the time of first exacerbation. All in all, a vast fog of confusion overshadows the everyday use of inhaled corticosteroids. We will try to dispel this fog and engender in the mind of the reader a practical approach to ICS in the context of asthma phenotypes. To do this, we first have to know the optimum starting dose of inhaled steroids.
What is the optimum starting dose of ICS?
In general, increasing the dose of inhaled corticosteroids is more effective than placebo therapy in preventing exacerbation, at least until patients become persistently symptomatic and regular users of ICS. The incidence of reduction in exacerbation with ICS, compared with the placebo, range 50% in severe asthma [17] . Given the impact of exacerbations on overall quality of life, this reduction is likely to be clinically significant.
Initial studies suggest that doubling the dose of maintenance ICS was as effective as giving oral corticosteroids at least in exacerbations occurring in outpatients with asthma [18] . There was a fall from 35.4 to 22.3 mild episodes of exacerbations per patient per year when low-dose and high-dose regimens were compared. The results in the group that received highdose budesonide, 800 μg, were marginally better than those who received low-dose budesonide plus formoterol, but not as good as those who received high-dose budesonide plus formoterol.
Still in the dark, we opted to know if this was a preventive measure of exacerbation or merely a consistent therapy for the upcoming exacerbation. Earlier literature in Cochrane Database Systematic Review 2003, after reviewing 12 papers and 26 trials [19] , revealed that initial moderate ICS doses appear to be more effective than initial low-dose ICS as the starting initial dose in asthma management. For example, while comparing moderate-dose ICS to low-dose ICS, there were significant improvements in morning PEFL/min from baselines [weighted mean difference (WMD), 11.14; 95% confidence interval (CI), 1.34-20.93] and nocturnal symptoms [standardized mean difference (SMD), 029; 95% CI, −0.53 to −0.06]. There were also an apparent, but clinically small improvement in the percent predicted FEV 1 (WMD, 5.32; 95% CI, 0.65-9.99) and nonsignificant improvements in morning peak expiratory flow (PEF) for high-dose ICS, compared with moderate-dose ICS [19] .
Other studies showed the benefits that by doubling the dose of inhaled corticosteroid, maintenance therapy are modest and generally inferior to those that result from adding other anti-inflammatory or bronchodilator agents to the treatment regimen [20] .
Doubling the dose of ICS
Eight studies by the Systemic Cochrane Review [17] , intended to compare the increasing dose of ICS versus the usual dose to treat asthma exacerbation in adult and children, showed that in a large number of asthma population with mild or moderate asthma, increasing ICS dose is unlikely to reduce the need for a course of oral steroids to treat attacks, prevent the need for an emergency visit with doctors or at the hospital, or to reduce the time it takes to recover. However, there was lot of variations in these studies.
Similarly, an effective strategy by GINA guidelines named the single maintenance and reliever therapy was approved few years ago. The only problem being that nobody can tell us when this transition went from a supposed benefit of higher ICS dose to a near-certain harm that might occur. But, wait a bit. Does it seem reasonable to administer a higher dose of ICS?
Until that uneasy transition zone of acute exacerbation, where we may lapse into remodeling and actually be harmed by the very same agents, we will look at the various causes of remodeling. The impact of treatment on remodeling is a heavily asked question.
Asthma remodeling
Acute inflammations that characterize exacerbation likely leads to lung tissue damage, which leads to the initiation of repair mechanisms that restore pulmonary structure and function. In the airway, the initiation of the repair process occurs very rapidly after injury, leading to the recruitment and proliferation of epithelial cells followed by redifferentiation into mature epithelium, together with delayed recruitment and proliferation of mesenchymal cells in subendothelial tissue. Persistence of excess connective tissue leads to peribronchial fibrosis, a characteristic feature of tissue remodeling with fixedairflow obstruction [21] . The important mediators involved, including transforming growth factor-β and fibronectin, are beyond the scope of this article.
The natural course of persistent airflow limitation in asthma is poorly known, but the reduced lung function at disease onset and an increased rate of exacerbation during adult life contribute to its development. Risk factors for progressive irreversible airway obstruction in asthma include adult-onset asthma, frequent exacerbations, smoking, occupational exposure, ongoing eosinophilic airway inflammation, airway hyper responsiveness, and polymorphism of the ADAM33 gene; all predict excess decline in lung function in asthma as well as at population level [22] .
However, these are not the only patients that have worsening symptoms due to remodeling. There are still others including a vast number of patients who have definable remodeling before being symptomatic.
Unfortunately, we still have a problem; what did the evidence-based medicine say?
Dose-response curve of inhaled corticosteroids in asthma treatment Current asthma management guidelines have been developed on the basis of two key assumptions. First, a dose-related difference in effect is anticipated. Therefore, patients with poorer lung function or control may benefit from stepping up the ICS doses. Second, those patients with more asthma severity, for example, those with increased frequency of symptoms, may benefit from higher dose compared with patients with less severe disease [23] .
The key findings among most literatures are that all inhaled corticosteroids demonstrated a dose-response relationship for efficacy measures. Nonetheless, most of the benefit in mild-to-moderate severity disease is gained in the low-to-moderate dose range. The Cochrane methodology has shown, unequivocally, that beclometasone dipropionate, budesonide, and fluticasone propionate lead to significant improvement in airway function, improvement of symptoms, reduced likelihood of asthma exacerbation, and a reduced need of rescue β2 agonist when any dose is compared with placebo [24] , but what a mess! Each of the above trials has its failings. They cannot provide clear insight into the relative effects of different doses because the trials did not randomize participants to different doses of ICS.
The FACET study showed that if the dose of inhaled corticosteroid is increased within the observed therapeutic dose range (100-500 μg/day fluticasone or equivalent), then the improvement with the increased dose of inhaled corticosteroid (in terms of reducing severe exacerbations) may be greater than that achieved by the addition of a long-acting β agonist [25] (Fig. 1 ). However, if the dose is increased beyond the top of the dose-response curve (>500 μg/ day of fluticasone or equivalent), then, not surprisingly, the improvement in asthma control is minimal, but a significantly greater benefit is obtained with the addition of the long-acting β agonist [27] [28] [29] . Thus, in other words, a moderate dose of ICS (500 μg/day fluticasone or equivalent) is preferable than adding LABA to lowdose ICS as in step-3 GINA guidelines, which is not consistent with the current guidelines.
It appears that the low and moderate doses of currently used ICS are in the flat part of the steroid dose-response curve. Thus, it is predicted that doubling the dose of ICS is not sufficient to significantly improve the lung function or reduce the symptoms. Rather, the data suggest that the increase in the dose of ICS should be at least fourfold to produce a clinically significant improvement in variables, such as symptoms, use of rescue β2-agonists, PEF, or lung function [26] . However, the steepness of the dose-response curve for different outcomes may vary. For example, an open dose-response evaluation of different sequential doses of budesonide in patients with mild-to-moderate asthma [26] shows that the dose-response curves for FEV1/PEF and forced expiratory flow at 25-75% are not identical. Similarly, the dose-response curves of budesonide on AMP and methacholine bronchial challenges were significantly different [26] .
In other words, a substantial increase of ICS signals the failure of merit mechanisms that maintain asthma control. If such impairment in control is large and sustained, it may cause the development of fixedairflow limitation and may be vital for stepping up to LABA. No wonder patients with severe asthma have such a poor prognosis! Therefore, we are left with two situations: either we get the boon of reducing the incidence of future exacerbation and/or remodeling with a higher dose of ICS or the bane of improving lung function through stepwise approach to LABA. We need to define the endpoints for any preventive measures that we undertake before any attempt to ameliorate airflow limitation.
These unfortunates probably present us with a rather unpleasant dilemma. There also seems to be little consensus on the role of high-dose ICS in acute exacerbation. What should we give? The general feeling in acute exacerbation seems to be that oral corticosteroids are desirable. The strategic plan is, in all cases, to condemn this approach.
We now know that in chronic heart failure, perhaps the worst thing we can do long term is to beat the heart further with inotropes. A considerable part of this beneficial effect may be related to the influence of Illustrates the dose-response curve of inhaled corticosteroids [26] . such agents on remodeling of the heart. Where remodeling is generally believed to be disadvantageous, in some way, it may serve a protective function. Paradoxically, in context of promising effects of these inotropes during acute heart failure, the tissues supporting the myocyte may turn out to be more important than the myocyte itself. This is analogous to the situation of remodeling in step-1 asthma management. Oh, it looks quite unequivocal. Perhaps, I am being a little unfair, but this statement should at least cause momentary concern in those who reflexively administer agents with unclear anti-inflammatory effects, such as LABA in favor of increasing ICS dose. The mechanisms by which ICS and LABA serve in remodeling are probably quite different and should not be equated.
Gardiner et al. [30] found no significant antiinflammatory effect on regular use of salmeterol therapy in airway inflammation, using bronchoalveolar lavage in asthmatic patients. Bronchodilators have pharmacological effect on remodeling through a protective effect or functional antagonism of bronchoconstriction and not related to any fundamental effect on airway structure [31] . On the other hand, there is also in-vitro evidence for the direct effect of inhaled steroids on the cells, growth factors, and cytokines thought to be central to the remodeling process [32] . In addition, the role of high-dose inhaled steroids on vascular remodeling in asthma had been studied in mildto-moderate cases, and results have shown a reduction of airway wall vascularity, evaluated as both vessel number and percent vascularity [33] .
As remodeling of the airway is thought to be a result of chronic inflammation within the bronchial wall, it follows that low-dose steroids showed steeper dose-response curve for effective measures in mild asthma, while moderate-to-high doses in moderate-to-severe asthmatics may reduce or reverse remodeling [24] .
Tomlinson et al. [34] advocated for the benefits of using higher doses of ICS in smokers; others have endorsed (or occasionally even tried to duplicate) this approach with varying degrees of success [35] . Currently, people seem to be shying away from high-dose inhaled corticosteroids based on the lack of evidence that it works in acute exacerbation.
Some food for thought
This seems to be the clearest indication for the use of a relatively higher dose of ICS, particularly if risk factors or fixed-airway flow limitation exist, notably, lower FEV 1 . Therefore, a correct approach might be to give treatment that will protect against exacerbation and/or declining of lung functions rather than focusing on time-to-first exacerbation. The boon of modification of independent risk factors, in favor of risk stratification-based medicine, is not illogical. Where gross and excessive airway limitation is present (as is almost always the case in severe asthma), it seems entirely reasonable to administer agents that antagonize inflammation and reduce the likelihood of future exacerbation. Although there is evidence of (and perhaps even a suspicion of) remodeling, addition of an agent that augments bronchodilation seems wise. A wealth of controversy has developed over the competing merits of various agents. Anyways, I will defer the discussion of efficient long-acting bronchodilators in a future article.
Role of long-acting β2 agonist bronchodilator
The addition of a LABA to ICS was not associated with a significant reduction in the rate of exacerbations requiring systemic corticosteroids, but was rather associated with a significant improvement in lung function compared with an ICS alone [19] . Similarly, compared with a double dose of ICS, the combination of a LABA and a lower dose of ICS did not significantly decrease the risk of exacerbations requiring oral corticosteroids, but it did result in significantly greater improvements in peak expiratory flow and caused significantly less growth impairment in children [19] .
Clinicians should also remain alert for another possible mechanism: the benefits of β2-agonists for symptoms could lead to an overreliance on asthma management. That is to say, if patients and their physicians are misled by the control of symptoms into thinking that the patient's underlying asthma is stable, necessary antiinflammatory treatment or other medications may be withheld, while the patient's disease becomes lifethreatening.
Severe attacks of asthma may also become the norm with the use of β agonists if sensitivity to bronchoconstrictive agents is decreased, although maximal airway narrowing is maintained, and attacks may occur more rapidly, as has recently been suggested [19] .
Bronchodilator tolerance, assessed by a reduction of the area under the salbutamol dose-response curve, occurred after one dose of formoterol (28% reduction; 95% CI, 12; 45%), increased in week 1and plateaued between weeks 1and 2(58% reduction, 95% CI, 38; 78%). Three days after stopping formoterol, the response to salbutamol was similar to baseline (12% reduction, 95% CI, 9; 33%) [36] (Fig. 2) .
Whatever the nature of the associations observed, whether they are causal relations or markers of severity, heavy use of these medications should send a clear signal to the patient and physician that the likelihood of a major adverse event is markedly increased and that further evaluation is needed.
Control and severity of asthma
Patient may perceive asthma as severe if he/she has intense or frequent symptoms, but this does not necessarily indicate a noncontrolled disease, as some other patients, despite maximum therapy, may still not show minimal symptoms or fewer exacerbations [11] . This might be pivotal in an attempt to differentiate asthma control from its severity.
What is meant by asthma control?
The level of asthma control is the extent to which the management of asthma can be observed in the patient or even reduced/removed by treatment. It is a complex interplay between the patient's genetic background, underlying disease processes, the treatment that they are taking, and environmental or psychological factors.
If we are waiting for asthma response to become 'adequately controlled,' we might miss the boat and fail to start proper agents timeously? Think about it; a man has good asthma control, but he is at an increased risk for future exacerbation because he had a history of previous severe exacerbations within the last year. Another patient has poor asthma control and additional risk factors for future exacerbations, for example, low lung function, heavy smoking, and poor medication adherence. The question to be addressed here is what, if any, different interventional therapies in asthma might be implemented in these two patients?
We may look to pulmonary functions that might help in the management for two different asthma phenotypes. Although pulmonary functions allow us to cover a fairly substantial range of symptoms or parameters and is often a realizable goal, its role does not ooze optimistism [37] . Perhaps, for patients having low FEV 1 who are poor perceivers, we will probably still be keeping their asthma as controlled as they may have had subtle symptoms! Note that, although low FEV 1 (below the upper normal limit) almost certainly implies abnormal lung function, the converse is not necessarily true, that is good FEV 1 need not imply asthma control! At the end of the day, lung function does not necessarily correlate with asthma symptoms in adults.
Assessing lung function with regular ICS treatment, FEV 1 starts to improve within days and reaches a plateau after ∼2 months. Remember also that the minimum tangible difference for improvement or worsening in FEV 1 , based on patient perception of change, has been reported to be about 10%. This could imply that if the control of asthma is obviously associated with a subtle change of FEV 1 (<10% change), unfortunately, similar lung function, but poorer control parameters may exist. If anything, we should assume that, in such patients, control is less − rather than more − exact. One explanation is probably because of a narrower range of tolerance for patients' symptomatology.
Although a trial of higher-dose ICS/LABA and/or systemic corticosteroids may be appropriate to see if FEV 1 could be improved, high doses should not be continued if there is little to no response. One important limitation for adjusting asthma medications, using lung function test, is the inbetween visit variability of FEV 1 (<12% week-toweek or 15% year-to-year in a healthy individual) [38] .
Lung function decline in asthma
One of the most vexing questions is how to dynamically assess pulmonary function. Progressive decline of lung function in asthma has been well recognized, but not fully understood. For example, in a Danish population study over 15 years, 1095 asthmatics showed a decline of FEV 1 to 38 ml/year compared with 22 ml/year in nonasthmatics [38] . However, accelerated decline is Area under the salbutamol dose-response curve on each study day. AUC results are expressed as percent recovery of the methacholineinduced fall in FEV 1 ×time [36] . AUC, area under the curve; FEV 1 , forced expiratory volume in 1 s. not invariable, and many asthmatics retain normal or close-to-normal lung functioning throughout their lifetimes.
More importantly, do exacerbations impact the rate of decline of lung function in asthma? Bai et al. [39] were the first to demonstrate such association, despite the fact that patients with frequent exacerbations had worse pulmonary function at baseline. Henceforth, if exacerbations predict a decline in function, does reduction in exacerbation reduce that decline? Or, in other words, is declining in lung function preventable?
Among patients followed for a median of 23 years, the mean annual decline in asthmatics was 20.6 ml/year after ICS initiation, compared with pretreatment [40] . Longer delay between the onset of asthma and the initiation of ICS contributes to reduced functional response to steroid therapy, as suggested by Selroos et al. [41] .
Adherence in assessment of control
This is not to say that asthma therapy is always sufficient, but, often in the hurly burly of fighting over 'which is best,' we tend to forget that without adherence to medications, ongoing declining of lung function would eventually catapult. Nonadherence is classified according to the WHO [42] into:
(1) Chronic underuse − the patient consistently uses less medication than prescribed, commonly SABA only. (2) Erratic adherence, in which medication use alternates between fully adherent (usually when symptomatic) and chronic underuse or total nonuse (when asymptomatic).
An empathic interventional approach could often be used to identify beliefs and behavior that may be a barrier to optimal treatment; for example, in patients with mild asthma who smoke, the response to ICS is attenuated, suggesting that adjustment to standard therapy may be required to attain asthma control. Another example would be that adolescents may be concerned about the impact of treatment on their physical or sexual capabilities, which can be adjusted for changing needs. Elder patients, as well, may not report asthma symptoms and may attribute breathlessness to normal aging or comorbidities, such as cardiovascular diseases and obesity. This highlights the impact of asthma phenotypes as a contributing factor into proper assessment of control [15] .
Asthma phenotypes
In the author's opinion, in the absence of counterevidence (asthma is only one entity), we should perhaps reach an agreement to accept different cohesive clear guideline for asthma phenotypes. We know that asthma is a complex heterogeneous syndrome with different phenotypes. Allergic asthma, for example, often commences during childhood and responds well to corticosteroids, while nonallergic asthma is less responsive to inhaled steroids. Another phenotype is the late-onset asthma, which is presented with asthma symptoms for the first time during adult life and often requires higher doses of ICS or is relatively refractory to corticosteroid treatment. Contemplate about fixed-airflow limitation with remodeling or asthma with obesity or asthma with little eosinophilic inflammation, and you will recognize what is meant by 'one size does not fit all.' Under any circumstances, there is a multitude of clinical clues that may provide evidence of uncontrolled asthma, including (but not limited to) information provided by the patient.
However, this may be difficult to assess in clinical practice, even though it is intimately associated with biological markers or biopsy-proven histological changes.
Defining asthma severity I do not know of any definitive answer to the above, but, with a gun held to my head, my partial answer would be that asthma severity is assessed when the patient has been on regular controller treatment for several months. It can be categorized into mild, moderate, and severe according to the patient's minimum effective level of treatment. This approach is based on the assumption that the patient is receiving appropriate treatment. This in theory is a very good notion, but fails to take into account the variable nature of asthma, environmental exposure, and psychological background. However, these are only surrogate measures, and it probably causes confusion.
An alternative concept is to shift from a symptomoriented stepwise approach to a dysfunction-centered asthma behavior. For more clarification, asthma that is fluctuating every now and then into variable medications, whatever they may be, should be considered as moderate. However, if its control is maintained or on a 'fixed medication,' it is said to be mild. On the contrary, asthma which is almost refractory to medication, probably because of fixedairway limitation, has to be considered as severe. In a nutshell, the level of variability in response to medication over time is the grounds on which we base asthma severity.
Conclusion
These contrasting pictures between increasing the dose of ICS and the escalation of LABA in case of acute exacerbation have to be revised and wrapped up. Asthma control and its severity are primarily assessed based on patients' symptoms. However, the response to treatment, although crucial from a clinical point of view, may not be exempted as a 'control,' since asthma symptoms vary in intensity within a short time, while control is an ultimate measurement performed longitudinally over time in terms of complications or exacerbations.
Therefore, in the context of escalation and deescalation therapies for asthma, one should consider the importance of modifying therapy of independent future risk factors, based on asthma phenotype clustering and not upon patients' symptoms, as is the case contemporaneously.
Asthma severity has to be considered in term of asthma 'behavior' rather than the level of given medication retrospectively.
Neither of the above has withstood scrutiny, but, in the author's opinion, the concept has to be changed from a symptoms-oriented stepwise approach to asthma impairment-behavior approach.
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